POZZI, Samantha
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.729
EU - Europa 5.375
AS - Asia 5.139
SA - Sud America 819
AF - Africa 187
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 7
Totale 24.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.545
GB - Regno Unito 2.065
SG - Singapore 1.530
CN - Cina 1.365
IT - Italia 824
HK - Hong Kong 653
BR - Brasile 596
VN - Vietnam 586
DE - Germania 525
SE - Svezia 452
FI - Finlandia 335
FR - Francia 253
UA - Ucraina 245
RU - Federazione Russa 230
TR - Turchia 169
IN - India 155
KR - Corea 124
ID - Indonesia 93
CA - Canada 91
BG - Bulgaria 87
AR - Argentina 71
BD - Bangladesh 71
IQ - Iraq 61
MA - Marocco 56
JP - Giappone 54
IE - Irlanda 50
NL - Olanda 46
MX - Messico 45
ZA - Sudafrica 42
ES - Italia 38
PH - Filippine 36
PL - Polonia 36
EC - Ecuador 33
PK - Pakistan 33
CO - Colombia 30
AE - Emirati Arabi Uniti 29
BE - Belgio 29
CL - Cile 25
LT - Lituania 24
AU - Australia 23
CZ - Repubblica Ceca 23
MY - Malesia 22
SA - Arabia Saudita 22
PY - Paraguay 19
EG - Egitto 18
UZ - Uzbekistan 17
VE - Venezuela 17
AT - Austria 15
CH - Svizzera 13
IR - Iran 13
DO - Repubblica Dominicana 12
NO - Norvegia 12
TN - Tunisia 12
CR - Costa Rica 11
JO - Giordania 11
UY - Uruguay 11
IL - Israele 10
KE - Kenya 10
PT - Portogallo 10
TW - Taiwan 10
AZ - Azerbaigian 9
HU - Ungheria 9
KG - Kirghizistan 9
PE - Perù 9
NZ - Nuova Zelanda 8
RO - Romania 8
TH - Thailandia 8
BO - Bolivia 7
BZ - Belize 7
DZ - Algeria 7
NG - Nigeria 7
DK - Danimarca 6
GH - Ghana 6
GR - Grecia 6
LB - Libano 6
NP - Nepal 6
TZ - Tanzania 6
BH - Bahrain 5
ET - Etiopia 5
KZ - Kazakistan 5
AL - Albania 4
BY - Bielorussia 4
CY - Cipro 4
EU - Europa 4
JM - Giamaica 4
KH - Cambogia 4
MD - Moldavia 4
OM - Oman 4
RS - Serbia 4
EE - Estonia 3
GP - Guadalupe 3
HR - Croazia 3
LV - Lettonia 3
PR - Porto Rico 3
QA - Qatar 3
SN - Senegal 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
Totale 24.248
Salva come PNG Salva come JPEG
Città #
Southend 1.620
Ashburn 1.303
Fairfield 1.270
Santa Clara 1.158
Singapore 1.004
Woodbridge 828
Chandler 644
Hong Kong 642
Houston 622
Ann Arbor 487
Seattle 467
Wilmington 455
Cambridge 450
San Jose 431
Jacksonville 418
Beijing 353
Dearborn 320
Nyköping 307
Hefei 292
London 258
Helsinki 242
Chicago 215
Ho Chi Minh City 196
Los Angeles 195
Modena 180
New York 177
Frankfurt am Main 144
Council Bluffs 141
The Dalles 139
Hanoi 138
San Diego 132
Seoul 112
Princeton 96
Salt Lake City 89
Sofia 84
Izmir 81
Eugene 79
Moscow 76
Shanghai 75
Munich 73
Milan 71
Lauterbourg 67
Jakarta 63
Buffalo 60
São Paulo 60
Rome 59
Dublin 48
Bremen 46
Casablanca 45
Dallas 42
Elk Grove Village 42
Redwood City 42
Falls Church 38
Des Moines 36
Columbus 35
Phoenix 35
Fremont 33
Tokyo 33
Orem 30
Tampa 29
Warsaw 29
Da Nang 28
Guangzhou 28
San Giuliano Milanese 28
San Francisco 27
Chennai 26
Boardman 24
Turku 24
Atlanta 23
Brussels 23
Montreal 23
Baghdad 21
Norwalk 21
Toronto 20
Bologna 19
Brooklyn 19
Lancaster 19
Belo Horizonte 18
Denver 18
Dong Ket 18
Haiphong 18
Rio de Janeiro 18
Sterling 18
Amsterdam 17
Johannesburg 17
Nanjing 17
Poplar 16
Boston 15
Buenos Aires 15
Dhaka 15
Manchester 15
Nuremberg 15
Ottawa 15
Paris 15
Parma 15
Quito 15
Stockholm 15
Miami 14
Detroit 13
Mexico City 13
Totale 17.674
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 609
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 594
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 514
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 511
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 484
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 437
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 425
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 425
Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report 402
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 401
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 384
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 380
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 377
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 372
Activity of BKM120 and BEZ235 against lymphoma cells 364
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 361
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 359
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 349
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 343
A concise review of lenalidomide therapy for follicular lymphoma 338
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 331
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 330
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 328
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 318
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 309
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 309
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 306
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells 304
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 303
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 300
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 297
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 296
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 296
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 282
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 282
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 282
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 277
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 275
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 273
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 271
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 271
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 270
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 268
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. 265
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 264
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 262
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 259
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. 256
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease 249
A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma 245
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 242
Low-molecular-weight heparin for vertebral artery dissection 239
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 235
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 234
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo 230
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 228
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 228
The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease 222
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma 217
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 217
Bortezomib and plasma cell leukemia 216
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 214
Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy 213
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 211
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 207
The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future 206
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. 198
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 beta 196
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. 193
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 193
Antiviral treatment with interferon +/- ribavirin after chemotherapy for diffuse large B-cell non-Hodgkin lymphomas with hepatitis C virus (HCV) infection 192
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice 181
Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma 176
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED FOLLICULAR LYMPHOMAS: LOW TOXICITY AND EXTENDED PROGRESSION FREE SURVIVAL. R1235 Barcelona, Spain. Bone Marrow Transplantation March 2004, Volume 33, Supplement 1 173
Bisphosphonates and Atypical Femoral Fractures 172
A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery 172
Role of thalidomide in previously untreated patients with multiple myeloma 169
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 164
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 164
Fatty acid synthase is a novel therapeutic target in multiple myeloma. 151
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity 141
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study 140
From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights 129
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 123
Clinical trials of bisphosphonates in multiple myeloma 120
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 118
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 113
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3Β activation and RNA polymerase II inhibition 108
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) 106
Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment 105
Autologous stem cell transplantation for newly diagnosed follicular lymphomas: low toxicity and extended progression free survival 96
Primary cardiac lymphoma: A case report and review 67
A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes 31
Totale 24.457
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.365
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.365
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021385 0 0 0 0 0 0 0 0 0 0 241 144
2021/20221.758 77 166 203 63 40 153 100 95 193 148 314 206
2022/20231.821 197 221 163 192 189 263 44 157 250 14 79 52
2023/20241.410 74 77 70 155 322 98 200 160 23 32 70 129
2024/20253.793 123 50 88 270 819 610 288 195 398 171 332 449
2025/20267.160 431 297 563 962 1.221 617 919 447 800 725 178 0
Totale 24.457